{"id":"dwp14012-y-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL5314922","moleculeType":"Small molecule","molecularWeight":"436.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DWP14012 works by inhibiting the enzyme DPP-4, which normally breaks down incretin hormones (GLP-1 and GIP) that regulate postprandial glucose levels. By preventing this degradation, the drug prolongs incretin action, stimulating insulin secretion and suppressing glucagon in a glucose-dependent manner. This mechanism reduces both fasting and postprandial blood glucose without causing hypoglycemia when used as monotherapy.","oneSentence":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:23.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04341454","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-06-02","conditions":"Acute Gastritis, Chronic Gastritis","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DWP14012 Y mg","genericName":"DWP14012 Y mg","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}